Foundry Partners’s Charles River Laboratories CRL Stock Holding History

Foundry Partners’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-45,863	Closed	-$6.17M	–	390
2018 Q3	$6.17M	Buy	45,863 +73	+0.2%	+$9.01K	0.23%	164
2018 Q2	$5.14M	Sell	45,790 -23,850	-34%	-$2.58M	0.21%	191
2018 Q1	$7.43M	Sell	69,640 -20,209	-22%	-$2.18M	0.32%	112
2017 Q4	$9.83M	Sell	89,849 -930	-1%	-$101K	0.41%	88
2017 Q3	$9.81M	Sell	90,779 -188	-0.2%	-$19.3K	0.39%	89
2017 Q2	$9.2M	Buy	90,967 +1,882	+2%	+$173K	0.38%	96
2017 Q1	$8.01M	Buy	89,085 +2,872	+3%	+$244K	0.33%	108
2016 Q4	$6.57M	Buy	86,213 +30,543	+55%	+$2.32M	0.28%	127
2016 Q3	$4.64M	Sell	55,670 -24	-0%	-$2.01K	0.24%	141
2016 Q2	$4.59M	Buy	+55,694	New	+$4.59M	0.26%	136

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Foundry Partners's CRL Position: Q4 2018 in Review

Foundry Partners sold out of Charles River Laboratories (CRL) in Q4 2018, closing a stake of 45,863 shares — an estimated $6.17M sold.

Foundry Partners first reported a position in CRL in Q2 2016 and held it in 10 quarters. The position peaked at $9.83M in Q4 2017. 407 funds tracked by Wall St. Rank hold CRL as of Q4 2018.

Foundry Partners reported no remaining Charles River Laboratories position as of Q4 2018 after selling out during the quarter.
Foundry Partners sold 45,863 Charles River Laboratories shares in Q4 2018, an estimated $6.17M.
Foundry Partners first reported a position in Charles River Laboratories in Q2 2016 and held it in 10 quarters.
Foundry Partners's Charles River Laboratories position peaked at $9.83M in Q4 2017.
407 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2018.

Based on Foundry Partners's 13F filing for Q4 2018, filed 10 Jan 2019.